Literature DB >> 29231163

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine
.

John Strang, Alastair Knight, Shelagh Baillie, Kylie Reed, Karolina Bogdanowicz, James Bell.   

Abstract

OBJECTIVES: To investigate plasma levels of buprenorphine and norbuprenorphine and their relationship to respiratory depression.
MATERIALS AND METHODS: Opioid-dependent subjects were randomized 2 : 1 to novel lyophilized rapid-disintegrating tablet ("bup-lyo") or standard sublingual buprenorphine tablet ("bup-SL"). Measurements included oximetry scores and linked plasma buprenorphine and norbuprenorphine levels.
RESULTS: Respiratory depression (cumulative duration of SpO<sub>2</sub> < 90% over 30-minute periods) increased with corresponding exposure levels (AUC<sub>30 min</sub>) of buprenorphine and particularly with norbuprenorphine. A lower buprenorphine/norbuprenorphine ratio was predictive of respiratory depression. The mean (SD) observed ratio was significantly higher for "bup-lyo" (3.4 (2.8)) compared to "bup-SL" (1.7 (0.77)), p < 0.0001.
CONCLUSION: Exploratory investigation found respiratory depression more strongly associated with norbuprenorphine than with buprenorphine. This accords with animal studies.
.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29231163     DOI: 10.5414/CP203118

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  2 in total

Review 1.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

2.  Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport.

Authors:  Tim Quach; Luojuan Hu; Sifei Han; Shea F Lim; Danielle Senyschyn; Preeti Yadav; Natalie L Trevaksis; Jamie S Simpson; Christopher J H Porter
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.